Opening the Black Box of Human Embryology: An Ethical Analysis of the Moral Status of Embryoids and Future of Embryoid Research
- Nisha Raval
- 5 hours ago
- 39 min read
Scientists estimate that up to 50% of fertilized eggs fail to develop, often before a pregnancy is even detected. Despite the fact that infertility, miscarriage, and developmental disorders affect millions of people, much of early human development remains hidden from direct observation and poorly understood. Emerging technologies known as embryoids, stem cell-derived models that mimic aspects of early development, offer new opportunities to study these processes while simultaneously raising difficult questions about moral status, regulation, and the boundaries of scientific research. This paper examines whether an ethical distinction exists between embryos and embryoids and explores what that distinction means for medicine, research, and society.
Table of Contents
Abstract
Introduction
Background Information
Descriptive Difference Between Embryos and Embryoids
Origin of Embryo and Embryoids
Legal Potential and the 14-Day Rule’s Application to Embryoids
Developmental Capacity
Biological Organization of Embryoids
Research Function and Scientific Potential of Embryoids
What is at stake?
Current Regulations and Legal Landscape
State-Level Variation and Legal Uncertainty
What is at stake?
Ethical Analysis
Stakeholders
Origin
Development and Potentiality
Does Developmental Capacity Matter?
Consequentialism
Utilitarianism
Deontology
Conclusion
My Stance
The Future of Embryoid Research
Featured image by Benvenisty, Nissim; modified by Vojtěch Dostál
Abstract
Using research on policy and regulation in the United States, this paper asks if there is an ethical and/or moral distinction between embryos and embryoids, and what the implications for clinical research, which benefits people, are if we do not draw an ethical distinction between human embryoids and embryos. This paper will use the frameworks of utilitarianism, deontology, and consequentialism to explore how an ethical distinction could be drawn and its impact on research practices for embryoids in comparison to embryos.
Introduction
Maya and Alex, a young couple, are interested in having a child. After a year of trying and being unsuccessful, they began medical testing. Everything looks normal on paper. There is no clear reason why pregnancy wasn’t happening, yet it still wasn’t. Their doctor explained that in many cases, conception can occur and still not lead to a viable pregnancy.
Pregnancy loss can sometimes occur before a person even realizes they are pregnant.
Eventually, Maya does become pregnant. For a brief moment, everything felt like it finally changed. But at her first appointment, the ultrasound showed that the embryo had stopped developing very early. The loss was quiet and medically common, but emotionally it felt
anything but ordinary as doctors couldn’t quite explain what happened. They called it the “black box of human embryology” or the critical, largely inaccessible, and poorly understood period of development occurring immediately after implantation, roughly from day 14 to day 28 after fertilization (Connor). This gap in knowledge is ethically significant because many decisions about embryo research and reproductive medicine are made despite limited understanding of the developmental period in which many pregnancies fail. As a result, restrictions on studying early development may shape not only scientific knowledge but also the ability to prevent pregnancy loss and improve reproductive outcomes. Many failed pregnancies like this taught Maya and Jordan something they had never understood before: that early human development is fragile in ways most people never see. Many pregnancies never progress far enough to be recognized. Some end without explanation. Others continue but involve lifelong challenges that begin long before birth. They also learned how often families around them carried similar stories in silence, stories of waiting, loss, and uncertainty that rarely appeared in everyday conversation. What once felt like a straightforward path to parenthood became, for them, a deeper understanding of how unpredictable and delicate the beginning of life can be.
Behind stories like Maya and Alex’s lies a much broader and often overlooked reality about human development. Scientists estimate that up to 50% of fertilized eggs fail to develop at all, often ending before a pregnancy is even detected (Liv Hospital International). Even among those actively trying to conceive, challenges are common: in the United States, about 1 in 5 (19%) married women aged 15 to 49 with no prior births are unable to get pregnant after one year of trying, and roughly 1 in 4 (25%) experience difficulty either becoming pregnant or carrying a pregnancy to term (CDC “Infertility: Frequently Asked Questions”). For those pregnancies that do begin, uncertainty continues, as approximately 10–20% end in miscarriage, with chromosomal abnormalities being the most common cause of spontaneous pregnancy loss in the first trimester (Dugas and Slane). Yet the impact of early development extends beyond pregnancy itself. About 1 in 6 children in the United States has a developmental disability, many of which originate during the earliest stages of embryonic and fetal brain development (CDC “Developmental Disabilities Data”). Additionally, 1 in 33 babies is born with a birth defect, conditions that contribute to roughly 20% of infant deaths (CDC "Birth Defects: Data and Statistics"). Strikingly, many of these developmental abnormalities occur before a person even realizes they are pregnant, reinforcing how much of early human development remains hidden, fragile, and still not fully understood. Taken together, these statistics demonstrate that early human development is not a rare scientific concern but a widespread medical and social issue. Understanding these developmental processes therefore has implications not only for scientific knowledge but also for millions of individuals affected by infertility, miscarriage, and developmental disorders.
Scientists have long sought to study early human embryonic development in order to understand the root causes of infertility and chromosomal abnormalities, but this research presents both practical and ethical challenges. One major issue is that the number of human embryos available for research is extremely limited, which restricts scientists’ ability to investigate early developmental processes. Additionally, in many countries, human embryos cannot legally be studied beyond the 14-day mark, despite the fact that many critical developmental processes occur after this point. This limitation stems from the “14-day rule,” originally established by the Warnock Committee and later adopted into international guidelines, including those of the International Society for Stem Cell Research (ISSCR), as a strict ethical boundary prohibiting in vitro development beyond 14 days or the formation of the primitive streak (1), which marks the onset of gastrulation, the establishment of the body axis, and the early stages of nervous system development (Sawai et al.). These milestones matter ethically because they are often used to justify when an entity acquires greater moral significance, making the 14-day rule not just a scientific boundary but a moral one. The rule is grounded in two primary scientific considerations: first, that prior to this stage the embryo can still divide into twins and therefore is not yet considered a distinct individual; and second, that the development of the nervous system, associated with the potential for sentience, begins around this time. For these reasons, the 14-day rule was adopted by numerous countries and organizations like the ISSCR, restricting scientific research in order to maintain respect for the moral significance of the embryo. However, it is precisely within these limitations that embryoids, embryo models made from human stem cells (2), enter the conversation (Sawai et al.). Embryoids provide scientists with powerful experimental models that mimic key aspects of early human embryonic development, allowing researchers to observe processes that would otherwise be extremely difficult to study. Created from pluripotent stem cells (3), embryoids can self-organize (4) into structures that replicate important developmental events such as germ layer formation and early patterning (5). Though they currently serve as important models for studying the earliest stages of human development, embryoids currently lack the complete cellular organization, developmental signaling, and extraembryonic structures necessary to support coordinated development into later fetal stages. These models therefore offer a controlled laboratory system for studying the molecular signals and genetic mechanisms that guide early development and for understanding how developmental errors may occur. Because embryoids are not created from fertilized eggs and do not have the same capacity of development as an embryo, they expand research opportunities beyond the constraints imposed on human embryos. This is particularly important because scientists estimate that many early developmental failures occur within the first two weeks after fertilization, a period that is normally hidden from direct observation (Zhang et. al). The significance of this capability is that embryoids provide access to developmental processes that are otherwise difficult or impossible to observe directly in humans, creating new opportunities for research while simultaneously raising questions about whether increasingly embryo-like models deserve greater ethical consideration. The technology also has practical medical implications: emerging research suggests that these models could help scientists better understand why embryos fail to implant during in vitro fertilization (IVF) and ultimately improve IVF success rates by revealing the biological conditions necessary for healthy early development. Together, these benefits could make embryoids an important tool for studying human development, improving fertility treatments, and advancing embryonic and developmental research (Kehoe).
(1) The Primitive streak is the initial band of cells from which the embryo begins to develop and it establishes and reveals the embryo’s head-tail and left-right orientations (Institute of Medicine and National Research Council).
(2) Stem cells are undifferentiated cells capable of self-renewal and developing into specialized cell types (Institute of Medicine and National Research Council).
(3) Pluripotent stem cells are stem cells capable of developing into cells from all three embryonic germ layers (ectoderm, mesoderm, and endoderm), allowing them to form nearly all cell types in the body but not an entire organism (Institute of Medicine and National Research Council).
(4) Self-organization refers to the ability of cells to spontaneously arrange themselves into organized structures and patterns without direct external construction (Dos Santos and Liberali).
(5) Early patterning is the process during early development in which cells establish spatial organization and positional information that determines future body structures (Ozair et al.).
While embryoids offer significant scientific and medical promise, their increasing similarity, as a result of improving scientific technologies, to natural human embryos raises difficult ethical questions that cannot be ignored. As technology advances and scientists continue to explore how to advance/modify these models in order to replicate more advanced stages of development, they challenge existing boundaries between what qualifies embryoids as a research tool and differentiates them from embryos, which are given moral consideration. This tension makes it necessary to examine not only what embryoids can do, but also how they should be treated. Central to this discussion is the concept of moral status.
Moral status is defined as the level of moral consideration an entity deserves for its own sake, rather than for its instrumental value to others (DeGrazia and Millum). Human societies typically understand moral status through two main frameworks. The existential (or intrinsic) construct treats moral status as an inherent property grounded in human existence itself. Under this view, moral worth is tied to membership in the human species, rather than to capacities such as consciousness or reasoning that are often associated with personhood. In other words, this framework separates biological humanity from functional definitions of a “person,” and argues that being human alone is sufficient for moral consideration. Because human beings possess moral status simply by virtue of existing as members of the species, this status is understood as intrinsic, inalienable, and non-conditional. Society’s role, therefore, is not to grant moral status but to recognize and respect it as something that already exists. In contrast, the relational construct understands moral status as dependent on characteristics or relationships, such as sentience, cognition, or social connection, that justify moral consideration. Rather than being automatically conferred by species membership, moral status emerges from these morally relevant traits and may be recognized or assigned within social and ethical systems. Unlike the intrinsic framework, this approach treats moral status as conditional and potentially variable depending on the characteristics an entity possesses (White). In this paper, these two contrasting frameworks will be used to examine how different traditions and policy systems determine moral status and to explore the ethical implications these definitions have for embryoids.
The debates over when a life begins and what defines the characteristics of a morally significant entity have been a central focus in ethics, law, religion, and medicine for years. As society and technology progress, this question has become increasingly relevant to decisions surrounding reproduction, medical research, and public policy. Advances in the fields of embryonic stem cell research and embryoid technologies have positioned embryos and embryoids and our understanding of the complexities of their moral significance and classification in a legally and ethically liminal space. The increased research and usage of these technologies has forced policy makers to grapple with the regulation of their usage and to balance their respect for human life and their duty to protect human lives. Using research on policy and regulation in the United States, this paper asks if there is an ethical and/or moral distinction between embryos and embryoids, and what the implications for clinical research, which benefits people, are if we do not draw an ethical distinction between human embryoids and embryos. This paper will use the frameworks of utilitarianism, deontology, and consequentialism to explore how an ethical distinction could be drawn and its impact on research practices for embryoids in comparison to embryos.
Background Information
Descriptive Differences Between Embryos and Embryoids
Origin of Embryos and Embryoids
For the purposes of this paper, a human embryo is defined as a living organism, not legally protected as a human being, derived from human gametes (sperm and egg) through fertilization or other means, and existing in the early stage of development from fertilization through the end of the eighth week of pregnancy, during which rapid cell division, uterine implantation, and the formation of major body systems occur (Harmon).
In contrast, embryoids are synthetic, lab-created models of early human development made from human stem cells such as embryonic stem cells (ESCs) or induced pluripotent stem cells. Also referred to as synthetic embryo models (SEMs), these structures are engineered to mimic specific early stages of embryonic development and can self-organize into formations resembling early human developmental patterns. As a result, embryoids can model processes including cell differentiation (6), tissue formation, early developmental organization, and implantation-like behavior (Marei).
(6) Cell differentiation is the process through which unspecialized cells become specialized cell types with distinct structures and functions (UCLA Broad Stem Cell Research Center).
Although on the surface embryos and embryoids may seem similar, important distinctions remain. Embryos are produced through the fusion of a natural egg and sperm, either via natural fertilization or IVF, whereas embryoids are artificially created from stem cells. They also differ significantly in developmental capacity: embryos are capable of developing into fetuses and eventually infants, while embryoids do not currently possess the developmental potential to become fetuses because of a lack of specific tissue development. This distinction is central to ethical debates because many arguments about moral status depend not simply on what an entity currently is, but on what it has the potential to become. At present, most SEMs are only permitted to develop up to the 14-day period or its developmental equivalent as development after that period is less predictable and more complex, which further complicates ethical research practices.
Legal Potential and the 14-Day Rule’s Application to Embryoids
The significance of this 14-day limit is closely tied to the historical development of embryo research regulations. As discussed earlier, the 14-day rule has long served as a key ethical boundary. In response to recent scientific advances, particularly the emergence of embryoids, the International Society for Stem Cell Research (ISSCR) revised this rule in 2021 by removing it as a strict universal limit for human embryo research and replacing it with a case-by-case ethical review framework. This change reflects the growing potential scientific benefits of studying later stages of development. However, it does not allow unrestricted research; instead, studies beyond 14 days now require rigorous ethical and scientific review (Sawai et al.). The guidelines emphasize that the ability to extend research does not automatically justify doing so. Ultimately, decisions about extending embryo research limits and considering limitations on embryoids are left to individual societies, requiring public discussion and regulatory approval, an issue that underscores the urgency of the ethical questions explored in this paper.
Developmental Capacity
Despite their artificial origin, embryoids resemble human embryos in several scientifically significant ways, particularly during the earliest stages of development. Like embryos, they can self-organize from pluripotent stem cells and undergo key processes such as germ layer formation, early patterning, and cell signaling that guide the development of body structures. Some advanced embryoid models can even form structures that closely resemble the primitive streak, though lacking complete/exact developmental integrity, marking the beginning of gastrulation and the establishment of a basic body axis. This increasing biological similarity complicates ethical distinctions because many regulatory frameworks rely on developmental milestones to determine when greater moral consideration should apply.
However, this resemblance remains incomplete in ways that are crucial to their moral evaluation. Unlike embryos, embryoids are not created through fertilization and therefore do not originate from the union of human gametes. More importantly, they currently lack the integrated developmental capacity required to progress into a fully formed human organism, as they do not develop the full range of embryonic and extra-embryonic tissues necessary for implantation and continued growth. While embryoids can model specific aspects of early human development with increasing accuracy, they do not possess the same potential for full human development (Rivron et. al).
Biological Organization of Embryoids
At a biological level, embryoids demonstrate how stem cells can differentiate into cells from all three embryonic germ layers: ectoderm (nervous system and skin), mesoderm (muscle, blood, and bone), and endoderm (digestive and respiratory organs). When grown in suspension, stem cells spontaneously differentiate into a mix of these cell types, showing broad developmental potential similar to early embryonic development. These capabilities matter ethically because they allow scientists to study developmental processes that would otherwise remain inaccessible, creating tension between potential medical benefits and concerns about increasingly embryo-like models.
Despite this potential, embryoids remain fundamentally limited compared to natural embryos. They lack the organized body plan and coordinated developmental program required for full organismal development, and differentiation within them occurs more randomly rather than through the structured processes seen in embryos. As a result, embryoids primarily function as experimental model systems used to study early developmental processes, test stem cell pluripotency (7), and investigate differentiation pathways in controlled laboratory environments (Sheridan et al.).
(7) Pluripotency: the capacity of individual cells to initiate all lineages of the mature organism in a flexible manner directed by signals in the embryo or cell culture environment (Smith).
Research Function and Scientific Potential of Embryoids
Because of these characteristics, embryoids have become valuable tools in scientific research. They allow scientists to better understand cellular processes and their impact on pregnancy and fetal development, particularly during the earliest stages when many pregnancies fail. Researchers use embryoids to study how development unfolds, why miscarriages occur, and what vulnerabilities exist during early embryonic stages. In addition, embryoids contribute to research on tissue and cell development, with applications in improving cell therapies and advancing organoid research.
Another major application of embryoids is disease modeling. Scientists use them to study genetic diseases and developmental disorders, observing how abnormal development emerges in early stages. Similarly, embryoids are used to test the effects of drugs and toxins on early development, providing insight into how external factors may influence fetal growth.
Currently, embryoids are not used in humans to develop a baby and remain confined to research settings. However, this limitation reflects the current stage of scientific progress rather than the absence of future potential (Marei).
Recent breakthroughs further highlight their potential. In 2022, researchers at the University of Cambridge created mouse synthetic embryo models (SEMs) that self-organized into structures containing a developing brain, a beating heart, and the foundations of other organs, closely resembling natural mouse development through approximately embryonic day 8–8.5, a stage occurring after gastrulation and body-axis formation. Importantly, these models were not human embryoids and therefore were not subject to the human 14-day rule. However, the research demonstrated that stem cell-based models can achieve greater levels of biological complexity than previously believed possible (Collins and Garget). Although current human embryoids remain substantially more limited in developmental capacity, these findings raise important questions about whether existing regulatory frameworks, many of which were designed around traditional embryos rather than embryo models, will remain sufficient as embryoid technologies continue to advance.
At the same time, advances in genetic modification add another layer of complexity. Scientists can edit or remove specific genes in stem cells before forming embryoids and then observe the resulting developmental changes. For example, deleting the gene PAX6, which is important for brain and eye development, produced embryoids with defects similar to those seen in natural embryos lacking that gene. This demonstrates the accuracy of embryoids as research models. However, as gene-editing technologies such as CRISPR-Cas9 continue to advance, this capability raises new ethical concerns. If embryoids gain enhanced developmental abilities through genetic modification, questions about their moral status and their comparison to human embryos become increasingly complex (Ruehl). These capabilities raise ethical concerns because they suggest that developmental limitations currently separating embryoids from embryos may not remain fixed, potentially weakening distinctions that many regulatory systems rely upon.
Section Summary
Taken together, these distinctions and developments highlight the complex position embryoids occupy at the intersection of science, medicine, and ethics. While they are not identical to human embryos in origin or developmental capacity, embryoids increasingly replicate key features of early human development, making them valuable tools for studying processes that are otherwise inaccessible. Their applications in disease modeling, drug testing, and fertility research demonstrate significant potential to improve medical understanding and outcomes, particularly in areas such as miscarriage, developmental disorders, and IVF success rates.
At the same time, rapid scientific advancements, including the ability to manipulate genes and create more complex, embryo-like structures, are beginning to blur the line between model and organism. This ambiguity is further complicated by an evolving regulatory landscape in which embryoids are not directly governed by existing laws but are instead shaped by policies originally designed for embryos. As a result, embryoids exist in a gray area: scientifically powerful yet ethically and legally uncertain. This tension underscores the need for a clearer framework to evaluate their moral status and determine how they should be treated as research continues to advance.
Current Regulations and Legal Landscape
In the United States, there are currently no explicit laws or regulations that directly govern embryoids or embryoid research. However, existing regulations on embryo-related research significantly shape how embryoids are studied and understood within scientific and legal contexts (Matthews and Morali). As a result, embryoid research operates within a largely indirect and evolving regulatory environment, guided by policies originally designed for human embryos rather than for synthetic models.
At the federal level, regulation of embryonic stem cell research is structured through a framework of key legal and policy guidelines, including the Dickey-Wicker Amendment, the policies of the International Society for Stem Cell Research (ISSCR), Executive Order 13505, and the National Institutes of Health (NIH) Guidelines for Human Stem Cell Research (“NIH Guidelines”). Together, these overlapping mechanisms establish the boundaries within which embryoid research is conducted.
The Dickey-Wicker Amendment provides the foundational legal restriction by prohibiting the use of federal funds for the creation or destruction of human embryos for research purposes. It also includes a broad legal definition, stating that “the term ‘human embryo or embryos’ includes any organism, not protected as a human subject under 45 CFR 46 as of the date of enactment of this Act, that is derived by fertilization, parthenogenesis (8), cloning (9), or any other means from one or more human gametes or human diploid cells.” This definition was originally intended to encompass a wide range of embryo-creation techniques and prevent federally funded researchers from creating or destroying embryos.
(8) Parthenogenesis is development in which an embryo-like structure forms using only maternal chromosomes without fertilization (Institute of Medicine and National Research Council).
(9) Cloning is a process used to create genetically identical copies of cells, tissues, or organisms (National Library of Medicine).
However, its application to embryoid models remains contested. Because embryoids are derived from stem cells rather than fertilization and typically lack the integrated developmental potential of a true embryo, it is unclear whether they fall within this definition. Consequently, embryoid research is often evaluated on a case-by-case basis by agencies such as the National Institutes of Health when researchers apply for funding.
Reviewers consider factors such as the complexity of the model and how closely it resembles an early human embryo in order to determine whether the research is permissible.
In addition to federal oversight, professional scientific organizations play a significant regulatory role. The International Society for Stem Cell Research (ISSCR) provides influential ethical guidelines that recommend specialized oversight for advanced embryo models, prohibit attempts to implant embryo-like structures into a uterus, and require strong scientific justification for experiments that mimic early human development. These guidelines, while not legally binding, shape research practices and reinforce ethical boundaries within the scientific community.
Further shaping this regulatory framework, Executive Order 13505, issued by President Obama in 2009, permits federal funding for responsible and scientifically worthy embryonic stem cell research within the limits of existing law. The NIH Guidelines build on this policy by outlining specific ethical standards and procedural requirements. These include mandates that embryonic stem cells must be derived from embryos originally created through IVF for reproductive purposes, that such embryos are no longer needed, and that they are donated voluntarily with informed consent. The guidelines also prohibit the creation of embryos specifically for research and forbid derivation through cloning, somatic cell nuclear transfer (SCNT) (10), or parthenogenesis, while ensuring that embryos are not obtained through financial inducement or coercion. Together, these policies create a regulatory structure that permits limited research while maintaining ethical constraints on the use of human embryos (NIH Guidelines for Human Stem Cell Research).
(10) Somatic cell nuclear transfer (SCNT) is the transfer of a cell nucleus from a somatic cell into an egg (oocyte) whose nucleus has been removed (Institute of Medicine and National Research Council).
State-Level Variation and Legal Uncertainty
Beyond federal policy, state laws governing embryo research vary significantly across the United States, often reflecting broader political and ethical divisions regarding reproductive rights and the moral status of early human life. In more conservative states, where greater emphasis is placed on protecting embryonic life, regulations tend to be more restrictive (Matthews and Morali).
For example, states such as South Dakota and Louisiana have enacted laws that prohibit most or all forms of research involving human embryos, including their creation, destruction, or use in scientific experimentation. While these laws are primarily directed at traditional human embryos, they create legal uncertainty for emerging areas of research such as embryoids. Regulatory uncertainty matters because unclear boundaries create inconsistent oversight, allowing similar research to be treated differently depending on funding source, institution, or jurisdiction
Louisiana, in particular, has established strict limitations on embryo research based on a public policy commitment to protecting embryonic life from the moment of fertilization. The state’s legal framework, including Louisiana Revised Statute § 9:122, reflects the position that human embryos should be used exclusively for reproductive purposes and not treated as research material, effectively granting them a heightened legal status (LA Rev Stat § 9:122 (2025) and Louisiana Health Law, ch. 3). Under this framework, researchers, IVF clinics, and other institutions are prohibited from creating embryos for research, destroying embryos for experimentation, or culturing embryos outside of reproductive intent.
These restrictions operate primarily at the institutional level but also affect individual researchers, as violations may result in professional discipline, loss of funding, or legal liability. Rather than relying heavily on criminal prosecution, enforcement is largely structural, functioning through institutional compliance, regulatory oversight, and potential civil consequences (SD Codified L § 34-14-17 (2025)). Although there is limited evidence of frequent direct enforcement or high-profile prosecutions, these laws have produced a significant chilling effect by discouraging institutions from pursuing embryo-related research within these states.
Section Summary
These policies demonstrate that embryoid research in the United States is governed not by a single comprehensive law, but by a layered system of broad statutory language, funding restrictions, institutional review processes, and professional ethical guidelines. This framework reflects the rapid pace of scientific advancement, as regulations originally designed for traditional embryos struggle to fully account for emerging technologies like embryoids.
As a result, oversight remains flexible but inconsistent, relying heavily on interpretation and case-by-case evaluation rather than clear, uniform standards. Taken together, these scientific developments and regulatory uncertainties suggest that the central ethical question is not simply whether embryoids resemble embryos, but whether the differences that remain are morally significant enough to justify treating them differently. The following sections therefore examine whether distinctions in origin, developmental potential, and biological organization provide sufficient ethical justification for separating embryoids from embryos in research and regulation.
Ethical Analysis
This brings us back to the central ethical question of this paper: Is there an ethical and/or moral distinction between embryoids and embryos, and what are the implications for clinical research, which benefits people, if we do not draw an ethical distinction between human embryoids and embryos?
Embryoids are often favored over embryos in scientific research due to ethical, legal, and supply constraints, yet this preference itself depends on the assumption that they occupy a different moral category. To evaluate this assumption, it is necessary to consider the various stakeholders involved and how their differing interests and concerns shape the debate because each group prioritizes different ethical principles, risks, and potential benefits when assessing the moral significance of embryonic and embryoid research. From there, key ethical values such as respect for life and the prevention of harm will be analyzed to determine how they apply to embryos and embryoids. Finally, these considerations will be examined through multiple ethical frameworks in order to assess whether a defensible moral distinction can be drawn and what that distinction means for the future of research.
Stakeholders
Patients struggling with infertility and people with developmental disorders are stakeholders because embryoid research could lead to improved fertility treatments and a better understanding of early human development. Scientists may use embryoids to study why embryos fail to implant or why miscarriages occur during the earliest stages of pregnancy. This knowledge could increase IVF success rates and help identify genetic or developmental problems earlier. For these patients, the research represents the potential for new medical options and healthier pregnancies.
Potential future children are stakeholders because advances in embryoid research could help prevent certain developmental disorders or birth defects before implantation occurs or pregnancy progresses.
Scientists are stakeholders because embryoids provide them with an opportunity to study early stages of human development that are otherwise difficult to observe. Restrictions on embryoid research could significantly affect the pace of scientific discovery in developmental biology and reproductive medicine, and take away a tool that is key to their research.
Doctors and fertility specialists are directly involved because discoveries from embryoid research could improve clinical practices related to reproductive health. Understanding early developmental processes may help physicians determine why embryos fail to implant or develop normally during IVF treatments. This knowledge could help fertility clinics refine embryo selection, reduce pregnancy loss, and increase successful outcomes for patients. As a result, medical professionals have a strong interest in how this research is regulated and applied in clinical settings.
Policymakers are responsible for creating the legal and regulatory frameworks that determine how embryoid research can be conducted. Governments must balance the potential benefits of scientific advancement with ethical concerns about the moral and/or legal status of embryoids. Regulations often determine funding availability, research limits, and oversight requirements for laboratories. Because their decisions shape the boundaries of scientific research, policymakers play a central role in resolving this ethical dilemma.
Disability rights advocates are important stakeholders because they are directly affected by how embryonic and genetic research is used, particularly in areas such as disease modeling, genetic screening, and the prevention of developmental disorders. On one hand, embryoid research has the potential to reduce suffering by improving understanding of genetic diseases, preventing certain conditions, and advancing medical treatments. On the other hand, some advocates raise concerns that such research may reinforce the idea that lives with disabilities are less valuable or should be prevented, contributing to stigma and discrimination (Boardman). In the context of this ethical dilemma, if no distinction is made between embryoids and embryos and research becomes more restricted, it could slow scientific progress that benefits individuals with disabilities. However, if a distinction is made and research expands, it may increase the use of technologies aimed at eliminating certain conditions before birth. Their perspective is therefore crucial in balancing medical advancement with inclusion and the inherent value of all human lives.
Society is also a stakeholder because biomedical research often relies on public funding and affects societal values about science and human life. Public opinion can influence government policies, funding priorities, and the acceptance of new medical technologies. At the same time, society stands to benefit from medical advances that could improve reproductive health and prevent developmental disorders.
While questions surrounding the public or private funding of embryoid research raise important ethical concerns, such considerations ultimately depend on whether this research is legally and morally permissible in the first place. As a result, this paper will not focus on funding structures, but will instead examine the more foundational ethical and legal distinctions between embryos and embryoids.
Together, these stakeholders demonstrate that the ethical debate over embryoids is not limited to scientific classification, but extends across medicine, policy, patient experience, and broader societal values. Each group brings different priorities, highlighting the tension between scientific progress, moral protection, and social responsibility.
Origin
The origin of embryoids provides an important ethical distinction that supports treating them differently from embryos. Because embryoids have a different origin than embryos, embryoids do not carry the same moral meaning associated with the beginning of human life. Unlike embryos, which are formed through fertilization and develop as unified human organisms, embryoids are created from human stem cells that are engineered in a laboratory to model specific aspects of early development. While they are derived from human biological material, they do not have the integrated structure or developmental potential to become a complete human organism. For this reason, their use in research does not raise the same ethical concerns about interfering with human reproduction or destroying an early stage of a developing human life. While embryoids still resemble early embryos and should be treated with appropriate ethical oversight, their artificial origin justifies assigning them a lower moral status and supports their use in research.
Development and Potentiality
When considering the difference between embryoids and embryos, one key distinction is their developmental capacities and their potential to become human persons. Currently, embryoids cannot fully develop into humans in the way embryos can, which supports the argument that their moral status is lower than that of embryos. Since they lack the ability to develop, they are more commonly viewed as biological models rather than entities with independent moral claims.
Additionally, embryo research is restricted beyond the 14-day limit, and embryos are not allowed to be researched past that developmental point. The rule reflects the idea that moral concern increases as an embryo develops key biological features associated with individuality and the potential for sentience, such as the formation of the primitive streak and the beginning of nervous system development. This suggests that moral status is, at least in part, linked to an entity’s capacity for structured, continuous human development. Embryoids differ in this respect because they do not possess the full developmental capacity of embryos and cannot progress through the complete sequence of embryonic development that leads toward a human organism. Since they do not reach the same biologically significant milestones that ground moral concern in the 14-day rule framework, embryoids are often seen as having a lower moral status and are therefore subject to fewer ethical restrictions in research contexts.
Does Developmental Capacity Matter?
One important question in evaluating developmental capacity is whether it matters if an embryo will never be given the opportunity to develop. In research contexts, embryos are explicitly donated with the understanding that they will not be implanted and will never result in a birth. From one perspective, this may weaken the moral importance of developmental potential, since the conditions necessary for that potential to be realized are intentionally absent.
However, from an intrinsic framework, developmental capacity is considered an inherent property of the embryo, independent of external circumstances. In this view, the decision not to implant does not eliminate moral significance. By contrast, a conditional framework may place less weight on unrealized potential, suggesting that embryos not intended for development could be treated differently from those with a realistic path to becoming a person. This distinction highlights an important tension in how developmental capacity is interpreted in ethical debates about embryos and embryoids.
Consequentialism
Consequentialism is the ethical view that the moral rightness of an action depends solely on its consequences, meaning the best action is the one that produces the best overall outcomes (Sinnott-Armstrong). From a consequentialist perspective, which evaluates actions based on their outcomes, not drawing an ethical distinction between embryoids and embryos would not be an ethical option because if embryoids are treated the same as embryos under regulation, they would likely become subject to the same strict legal and ethical restrictions, which would significantly limit embryoid research.
As a result, research using embryoid models, currently designed to provide a controlled and ethically regulated way to study early human development, would likely decrease. This could slow scientific progress in infertility treatment, miscarriage prevention, and developmental disorder research. Importantly, this does not necessarily mean research would become more ethical or better supervised; instead, it may simply shift research away from highly regulated embryoid systems or restrict it altogether.
From this perspective, failing to distinguish between embryos and embryoids could reduce access to valuable scientific tools that are specifically designed to balance ethical concerns with medical advancement. At the same time, treating them as morally equivalent may increase ethical consistency and public trust, particularly among groups who believe embryos possess strong moral status. However, this comes at the cost of delayed or reduced medical benefits, especially for individuals experiencing infertility or recurrent pregnancy loss.
However, this conclusion depends heavily on which stakeholders and outcomes are prioritized. The argument for maintaining a distinction between embryos and embryoids largely emphasizes consequences for researchers, patients experiencing infertility or pregnancy loss, and individuals who may benefit from advances in developmental medicine. From an alternative consequentialist perspective, society itself may be considered the primary stakeholder. Under this view, failing to treat embryoids and embryos similarly could be seen as producing negative consequences by weakening societal respect for human life or potential human life, reducing public trust in scientific institutions, or creating discomfort around increasingly human-like biological models.
Utilitarianism
Utilitarianism is an ethical framework that states that an ethical decision is one that creates the greatest good for the greatest number of people (Nathanson). From a utilitarian lens, embryoid research would be considered ethically justified because it has the potential to produce significant benefits for society. By allowing scientists to study early human development, embryoids could help researchers understand why miscarriages occur, improve IVF success rates, and identify causes of developmental disorders. These advances would reduce suffering for many patients struggling with infertility or genetic conditions developed during pregnancy. Furthermore, embryoids would provide a way to study early development without relying heavily on scarce human embryos, which would improve research quality and yield.
However, if embryoids were granted the same moral status as human embryos, many forms of embryoid research could face restrictions similar to those applied to embryo research. This could significantly limit scientists’ ability to study early human development, since embryoids are currently one of the few models that allow researchers to observe processes that occur during the earliest stages after fertilization. Reduced access to these research models could slow progress in improving IVF outcomes, understanding miscarriages, and identifying the origins of developmental disorders. From a utilitarian perspective, this restriction may produce greater overall harm by preventing scientific advances that could benefit many patients and families.
On the other hand, some may argue that failing to distinguish between embryoids and embryos protects entities that closely resemble early human life from instrumental use in research. This perspective emphasizes moral caution and the importance of not treating life-like biological structures purely as tools, even if they are not fully equivalent to embryos in developmental capacity.
Ultimately, through this utilitarian analysis, the societal benefits of continued embryoid research outweigh the potential moral costs of not extending the same ethical protections given to embryos.
Deontology
Deontology is an ethical theory that judges the morality of an action based on rules, duties, or obligations, rather than the consequences (Alexander and Moore). From a deontological perspective, society has a duty to protect vulnerable forms of life, especially in this case where their lives are not as significant as humans, but are still closely correlated with human life. Deontological ethics emphasizes the importance of respecting entities that possess inherent value rather than treating them purely as tools for achieving beneficial outcomes. Protecting vulnerable life in this context is not necessarily based on proven personhood, but on the principle of respect for intrinsic value that states that entities closely connected to human development should not be used instrumentally without serious moral consideration (Holy-Luczaj and Blok).
Another duty that may arise within a deontological framework is the protection of responsible scientific and medical progress. Society often recognizes a moral obligation to support research that can alleviate suffering, improve health outcomes, and advance knowledge about human biology. Embryoid research has the potential to help scientists understand early developmental failures, improve IVF success rates, and identify the causes of certain developmental disorders. If embryoids do not possess the same moral status as embryos, restricting their use could prevent important discoveries that benefit patients and families. Society therefore has a duty to allow ethically regulated research that contributes to medical advancement.
One important consideration in this ethical dilemma is the use of entities as means to an end. If embryoid use is justified on the basis that it allows for the progression of knowledge and yields information beneficial to the greater public, it raises the question of whether entities that closely resemble early human embryos can be ethically used as research tools. Through a deontological framework, using entities with potential moral significance for instrumental purposes would be particularly concerning. If embryoids are viewed and regulated similarly to embryos, using them only to achieve scientific and medical outcomes could be seen as failing to respect their moral status. However, if embryoids are viewed as having a lesser moral status than embryos, their instrumental use becomes more ethically permissible.
Finally, from the perspective of respect for human life, embryoids would be seen as ethically preferable research subjects when compared with embryos. The value of respect in bioethics centers on the idea that human life, even in its earliest stages, should not be treated as a means to an end. Because embryos originate from fertilization and possess the inherent biological capacity to develop into a human being if implanted, it can be argued that they deserve a special level of moral respect. Destroying embryos for research would therefore be seen as instrumentalizing a form of human life that carries the potential for personhood. Embryoids, however, lack the biological capacity to develop into a full human organism. Because they do not possess this potential, using them for research does not involve ending the developmental trajectory of a possible human life. In this way, embryoid research better aligns with the value of respect for human life by allowing scientists to study early developmental processes without creating and destroying fertilized embryos.
From a legal perspective, the question of whether embryoid research respects human life is approached through how laws define and regulate embryos. In general, legal systems interpret “respect for human life” by placing restrictions on how human embryos can be created, used, and destroyed. For example, policies such as the Dickey-Wicker Amendment and various state laws limit or prohibit the use of embryos in research, reflecting a legal judgment that embryos should not be treated purely as tools for scientific advancement. In this sense, the law expresses respect for human life by restricting the instrumental use of entities that are closely tied to human development.
When applying this reasoning to embryoids, the issue becomes more complicated. Because embryoids are not created through fertilization and do not clearly meet the legal definition of an embryo, they are often not subject to the same restrictions. As a result, the law currently allows their use in research in ways that would not be permitted for embryos. This can be interpreted in two ways. On one hand, allowing embryoid research may support respect for human life by reducing the need to use and destroy actual embryos. On the other hand, as embryoids become more similar to embryos in structure and function, the legal distinction may begin to weaken. If embryoids closely resemble the very entities the law aims to protect, continuing to treat them as merely research tools could challenge the consistency of how respect for human life is applied. Ultimately, legal systems have yet to fully resolve this issue, and interpretations remain dependent on existing definitions and regulatory frameworks. As embryoid technology advances, laws may need to adapt in order to determine whether these models should remain distinct from embryos or be granted similar protections.
From a religious perspective, the question of whether embryoid research respects human life depends largely on how moral status is understood within two major frameworks: intrinsic and conditional.
Under the intrinsic framework, which is common in many religious traditions such as Catholicism, human life is believed to possess moral value from the moment of fertilization because it is created in the image of God. Within this view, respect for human life requires that any entity with the potential to become a human being must not be treated merely as a means to an end. Because embryos originate from fertilization and carry the potential for complete development, their use in research is often considered a violation of respect for human life. Embryoids, however, complicate this framework. Since they are not created through fertilization and do not possess the same natural developmental trajectory, some may argue that they do not qualify as human life in the same intrinsic sense. From this perspective, using embryoids for research may still align with respect for human life, as it avoids the destruction of fertilized embryos while still advancing scientific knowledge. However, others may argue that as embryoids become increasingly similar to embryos, using them instrumentally risks undermining the broader principle of respect for human life by blurring the moral boundary between natural and synthetic life.
Under the conditional framework, which bases moral status on characteristics such as sentience, consciousness, or developmental capacity, embryoids are more clearly distinguished from embryos. Because embryoids lack the integrated potential to develop into a full human organism and do not possess capacities like consciousness or sentience, they are assigned a lower moral status. From this perspective, respect for human life does not require treating embryoids with the same moral consideration as embryos. Instead, their use in research can be ethically justified if it contributes to meaningful scientific or medical advancements. In this way, embryoid research may be seen as consistent with respect for human life, as it enables the study of early development, the prevention of disease, and the improvement of fertility treatments without directly harming entities that possess full moral status. However, even within this framework, limits may still exist, as increasing complexity in embryoids could gradually strengthen claims to moral consideration, requiring ongoing ethical evaluation.
Taken together, these ethical frameworks demonstrate that embryoids occupy a complex position between scientific model and morally significant entity. While their artificial origin and limited developmental capacity support treating them differently from embryos, their increasing biological complexity continues to blur this distinction. Ultimately, whether a meaningful ethical difference exists depends on the framework used, and this determination has significant implications for the future of clinical research and the moral boundaries of early human development.
Conclusion
This paper began with a simple but unsettling observation: that the earliest stages of human development are not only biologically fragile, but largely invisible. Through the story of Maya and Alex, and through the broader scientific reality of high rates of early developmental loss, we were first introduced to the idea that much of early development unfolds in a space we rarely see or fully understand. This space became more visible through embryoid research, an innovation that both promises insight and raises difficult ethical questions about what exactly is being modeled, and what that model morally represents.
Therefore, embryoids and embryos were placed side by side, not as identical entities, but as increasingly difficult ones to separate in practice. What initially appears to be a clear scientific distinction based on origin and developmental capacity gradually becomes more ethically unstable as embryoids grow more complex and embryo-like. At the same time, existing laws and regulatory systems revealed a similar tension: they were built around the moral and legal status of embryos, yet are now being stretched to fit technologies they were never designed to address. The result is not a clear answer, but a shifting boundary line that depends heavily on interpretation.
When moral status was examined through different ethical frameworks, this ambiguity only deepened. Utilitarian and consequentialist perspectives tended to emphasize the large-scale benefits of embryoid research, particularly its potential to improve fertility treatments, reduce miscarriage, and expand understanding of early development. Deontological concerns, however, pushed in the opposite direction, focusing on duties of respect toward life-like biological entities and the risks of treating anything resembling human development purely as a tool, showing that moral status itself is not a single standard, but something shaped by competing beliefs about origin, potential, and inherent value.
By the end of this analysis, the question is no longer simply asking whether embryoids and embryos are the same or different, but instead recognizing that the complexities lie in how societies choose to define and draw that boundary in the first place. The distinction is not only scientific, but it is moral, legal, and deeply interpretive, and because embryoids exist precisely in the space where those categories overlap, they force a broader question: whether our current ethical frameworks are flexible enough to keep pace with the science they are meant to regulate.
What emerges is not a final resolution, but a clearer sense of where the debate now sits. Embryoids are neither fully separate from embryos nor fully equivalent to them; they occupy a middle ground that is still being actively constructed through research, policy, and ethical reasoning. The implications of this uncertainty extend beyond laboratories, influencing how we think about the beginning of human life, the limits of scientific intervention, and the responsibilities that come with expanding biological knowledge.
Ultimately, the central question of this paper does not end with a definitive answer, but with a reframing: the ethical challenge is not only whether a distinction exists between embryos and embryoids, but how that distinction should be drawn, and what is gained or lost each time we choose where to place it.
My Stance
Based on the ethical analysis in this paper I believe that, at this point in time, there is a moral distinction between embryoids and embryos that needs to be carefully defined, protected, and regularly updated as technology progresses in order to allow scientific research to progress in an ethical manner. By choosing not to make a distinction, we risk failing to acknowledge the rapid pace of technological advancement. In doing so, we allow that progress to proceed without sufficient ethical guidance, rather than maintaining a clear understanding of it and ensuring that humanity’s future remains responsibly protected.
The utilitarian and consequentialist reasoning makes it difficult to dismiss the substantive benefits that embryoid research offers, particularly in reducing suffering associated with infertility, improving the success rates of reproductive technologies, and expanding scientific understanding of early human development. Taken seriously, these outcomes generate a strong moral case for continued and even expanded research, since they suggest that restricting embryoid studies could carry real costs for present and future patients. At the same time, the deontological framework and concerns about respect for life introduced an important counterweight, reminding us that scientific capability does not automatically justify scientific action grounded solely in its outcomes. When research objects begin to resemble early stages of human life, questions of duty, respect, and the limits of instrumentalization and treating biologically human-like systems too casually become unavoidable, even if the potential benefits are substantial. Across these frameworks, a pattern becomes clear: the ethical issue is not whether advancement is valuable, but how far advancement should extend without reflection and how moral boundaries should be drawn in response to technologies that could have both beneficial and harmful impacts. In other words, the ethical problem is not the presence of benefit, but the absence of clear criteria for determining when benefit should be limited by moral constraint.
This is where my own values became central to how I interpret the distinction between embryos and embryoids. I value scientific and medical progress, especially when it has the potential to reduce suffering and improve human life. At the same time, I also believe that progress cannot be the only guiding principle and balancing the harms and benefits of progress should be equally valued and evaluated. The fact that something can be done does not necessarily mean it should always be done, especially in this case where what is being created or manipulated begins to shift the meaning of human life. In the case of embryoids, the concern is not just about what they are today, but about what they may become as technology continues to evolve. Without a clear ethical distinction, advancement risks becoming directionless and driven more by possibility than by intentional limits. Balancing these two ideas, the value of progress and the necessity of restraint, leads to the conclusion that ethical clarity is not a barrier to science, but a condition for ensuring that science remains accountable to the humanity it is meant to serve.
With this, I think the key distinction between embryoids and embryos lies in their biological role and developmental capacity. Embryoids are artificial structures created from stem cells to model specific aspects of early development for research, meaning they are limited systems that simulate biological processes without forming a complete organism. Embryos, by contrast, are naturally formed with an egg and sperm and possess the integrated and continuous capacity to develop into a full human being. This difference matters because moral significance is often tied to the potential for full human development and individuality. Since embryos represent the beginning of an organism with that potential, they are treated as having higher moral status, whereas embryoids, which lack the ability to develop into a human life and function instead as experimental models, are not subject to the same level of moral concern.
The Future of Embryoid Research
Looking forward, one of the most significant possibilities in embryoid research is the continued progression of their developmental capacity. At present, much of the ethical justification for their use in research rests on the assumption that embryoids lack the integrated biological potential to fully develop into human beings. This distinction has been central to many of the arguments in this paper: it has allowed embryoids to be treated as scientifically valuable models rather than morally equivalent entities to embryos, thereby making their use in research more ethically defensible under both consequentialist and conditional frameworks of moral status.
However, if scientific progress continues at its current pace, this foundational distinction may eventually become less clear. Previously discussed research on mouse SEMs at Cambridge, where models developed essential foundational organs, demonstrates that this could become a realistic future possibility for human embryoids (Collins and Garget). A future in which embryoids are capable of developing more fully, potentially approaching or even reaching stages of development previously thought to be exclusive to embryos, would fundamentally alter the ethical landscape. In such a scenario, the justification that embryoids lack developmental potential, and therefore may be more permissibly used in research, would no longer apply in the same way. The moral reasoning that currently supports their use would be weakened, not because the value of scientific progress has diminished, but because the characteristics used to ethically distinguish them from embryos would have changed.
This possibility raises a deeper concern about how ethics will function in the face of rapid scientific change. If embryoids can be increasingly edited, structured, and guided in ways that parallel embryonic development, specifically through technologies such as gene editing or advanced stem cell manipulation, then the boundary between model and organism becomes increasingly difficult to maintain. In that context, continued reliance on present distinctions risks becoming ethically outdated, grounded in assumptions about biological limitations that no longer reflect scientific reality.
As a result, the ethical framework developed throughout this paper would need to be reconsidered. Much of the current justification for the use of embryoids depends on their reduced developmental capacity and their separation from the natural process of human reproduction. If those conditions were to change, the moral distinction between embryos and embryoids would require reevaluation from the ground up. In other words, if science reaches a point where embryoids more closely resemble embryos in both structure and developmental potential, then the ethical assumptions that currently guide their use may no longer be sufficient to support existing policy or practice.
Ultimately, this does not invalidate the conclusions drawn in the present analysis, but it does highlight their conditional nature. The ethical distinction between embryos and embryoids is not fixed; it is dependent on the state of scientific knowledge and technological capability at a given moment in time. For that reason, the most important implication of this discussion may not be a permanent answer, but a continuing responsibility: to revisit and reassess these ethical boundaries as science evolves. If embryoids one day cross the threshold from model to fully developmental entity, then the question posed in this paper will have laid the groundwork to allow for future discussion to build on it in an entirely new way.
Works Cited
Alexander, Larry, and Michael Moore. “Deontological Ethics.” Stanford Encyclopedia of Philosophy, Stanford University, 11 Dec. 2024, https://plato.stanford.edu/entries/ethics-deontological/. Accessed 5 June 2026.
"Birth Defects: Data and Statistics." Centers for Disease Control and Prevention, www.cdc.gov/birth-defects/data-research/facts-stats/index.html.
Boardman, Felicity Kate. "The Expressivist Objection to Prenatal Testing: The Experiences of Families Living with Genetic Disease." Social Science & Medicine, vol. 107, 2014, pp. 18–25. Elsevier, https://www.sciencedirect.com/science/article/pii/S0277953614001294
"Cloning." MedlinePlus, U.S. National Library of Medicine, medlineplus.gov/cloning.html.
Collins, Sarah, and Garget, Jacqueline. "Synthetic Embryo with Brain and Beating Heart Grown from Stem Cells by Cambridge Scientists." University of Cambridge, 25 Aug. 2022, www.cam.ac.uk/stories/model-embryo-from-stem-cells.
DeGrazia, David and Millum, Joseph "Moral Status." Theory of Bioethics, Cambridge University Press, 2003, pp. 19–48, www.cambridge.org/core/books/theory-of-bioethics/moral-status/0A0B4D7E1829D937C91CB456E5B27925.
"Developmental Disabilities Data." Centers for Disease Control and Prevention, Environmental Health Tracking, www.cdc.gov/environmental-health-tracking/php/data-research/developmental-disabilities.html.
Dugas C, Slane VH. Miscarriage (Archived) [Updated 2022 Jun 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532992/
“Guidelines for Human Stem Cell Research.” National Institutes of Health Stem Cell Information, U.S. Department of Health and Human Services, https://stemcells.nih.gov/research-policy/guidelines-for-human-stem-cell-research. Accessed 5 June 2026.
Harmon, Angela. "Embryo." EBSCO Research Starters: Anatomy and Physiology, EBSCO, www.ebsco.com/research-starters/anatomy-and-physiology/embryo.
Holy-Luczaj, M., Blok, V. Hybrids and the Boundaries of Moral Considerability or Revisiting the Idea of Non-Instrumental Value. Philos. Technol. 34, 223–242 (2021). https://doi.org/10.1007/s13347-019-00380-9
"Infertility: Frequently Asked Questions." Centers for Disease Control and Prevention, 15 Dec. 2023, www.cdc.gov/reproductive-health/infertility-faq/index.html.
Institute of Medicine and National Research Council. 2008. 2008 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research. Washington, DC: The National Academies Press.
Kehoe, John. "How These Tiny Embryoids Could Improve IVF Outcomes." Australian Financial Review, 8 Nov. 2023, www.afr.com/technology/how-these-tiny-embryoids-could-improve-ivf-outcomes-20231108-p5eil5.
“Louisiana Health Law, Chapter 3: Human Embryos.” Louisiana State University Law Center, https://biotech.law.lsu.edu/cases/la/health/embryo_rs.htm. Accessed 5 June 2026.
“Louisiana Revised Statutes Title 9, § 122: In Vitro Fertilized Human Ovum; Juridical Person.” Justia US Law, https://law.justia.com/codes/louisiana/revised-statutes/title-9/rs-9-122/. Accessed 5 June 2026.
Marei, Hany E. "Stem Cell and Synthetic Embryo Models: Advances, Applications, and Ethical Considerations." Stem Cell Reviews and Reports, vol. 21, no. 6, 2025, pp. 1648–1668, doi.org/10.1007/s12015-025-10890-z.
Matthews, Kristin R W and Morali, Daniel. "Can We Do That Here? An Analysis of US Federal and State Policies Guiding Human Embryo and Embryoid Research." Journal of Law and the Biosciences, vol. 9, no. 1, 9 June 2022, Article lsac014, pmc.ncbi.nlm.nih.gov/articles/PMC9183789/.
Nathanson, Stephen. "Utilitarianism: Act and Rule." Internet Encyclopedia of Philosophy, iep.utm.edu/util-a-r/. Accessed 5 June 2026.
Ozair MZ, Kintner C, Brivanlou AH. Neural induction and early patterning in vertebrates. Wiley Interdiscip Rev Dev Biol. 2013 Jul;2(4):479-98. doi: 10.1002/wdev.90. Epub 2012 Oct 15. PMID: 24014419; PMCID: PMC6945772.
Rivron, Nicolas C., et al. "Blastocyst-like Structures from Mouse Embryonic and Trophoblast
Stem Cells." Nature, vol. 557, 2018, pp. 106–111, pmc.ncbi.nlm.nih.gov/articles/PMC6945772/.
Ruehl, Isabel. “Lab-Grown ‘Embryoids’ Offer New Window into Gene-Trait Relationships.” The Transmitter: Neuroscience News and Perspectives, 26 Oct. 2022, https://doi.org/10.53053/EBNI9621.
Sawai T, Okui G, Akatsuka K, Minakawa T. Promises and rules: The implications of rethinking the 14-day rule for research on human embryos. EMBO Rep. 2021 Sep 6;22(9):e53726. doi: 10.15252/embr.202153726. Epub 2021 Aug 16. PMID: 34396683; PMCID: PMC8419696.
Sheridan SD, Surampudi V, Rao RR. Analysis of embryoid bodies derived from human induced pluripotent stem cells as a means to assess pluripotency. Stem Cells Int. 2012;2012:738910. doi: 10.1155/2012/738910. Epub 2012 Mar 1. PMID: 22550517; PMCID: PMC3328185 .
Sinnott-Armstrong, Walter. "Consequentialism." Stanford Encyclopedia of Philosophy, edited by Edward N. Zalta, Stanford University, 2019, plato.stanford.edu/entries/consequentialism/.
Smith, Austin. "Design Principles of Pluripotency." EMBO Molecular Medicine, vol. 1, no. 5, 2009, pp. 251–254. PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC3378137/. Accessed 4 June 2026.
“South Dakota Codified Laws § 34-14-17: Research on Human Embryos Prohibited.” Justia US Law, https://law.justia.com/codes/south-dakota/title-34/chapter-14/section-34-14-17/. Accessed 5 June 2026.
UCLA Broad Stem Cell Research Center. “Differentiation.” UCLA Stem Cell Glossary, University of California, Los Angeles, https://stemcell.ucla.edu/glossary/differentiation. Accessed 5 June 2026.
"What Percentage of Fertilized Eggs Fail to Develop?" Liv Hospital International, int.livhospital.com/what-percentage-of-fertilized-eggs-fail-to-develop/.
White FJ. Personhood: An essential characteristic of the human species. Linacre Q. 2013 Feb;80(1):74-97. doi: 10.1179/0024363912Z.00000000010. PMID: 24845541; PMCID: PMC6081772.
Xavier da Silveira Dos Santos A, Liberali P. From single cells to tissue self-organization. FEBS J. 2019 Apr;286(8):1495-1513. doi: 10.1111/febs.14694. Epub 2018 Nov 19. PMID: 30390414; PMCID: PMC6519261.
Zhang, Miaoci, Alice H. Reis, and Mijo Simunovic. “Human Embryoids: A New Strategy of Recreating the First Steps of Embryonic Development in Vitro.” Seminars in Cell & Developmental Biology, vol. 141, 2023, pp. 14–22. ScienceDirect, https://doi.org/10.1016/j.semcdb.2022.07.003.
Comments